Print Page     Close Window     

SEC Filings

10-K/A
BIOTIME INC filed this Form 10-K/A on 03/29/2017
Entire Document
 

ASTERIAS BIOTHERAPEUTICS, INC.
BALANCE SHEET
(IN THOUSANDS EXCEPT PAR VALUE AMOUNTS)

   
December 31,
2016
   
December 31,
2015
 
         
(see Note 10)
 
ASSETS
           
CURRENT ASSETS
           
Cash and cash equivalents
 
$
19,800
   
$
11,183
 
Available-for-sale securities, at fair value
   
15,269
     
17,006
 
Landlord receivable
   
-
     
567
 
Prepaid expenses and other current assets
   
1,921
     
1,033
 
Total current assets
   
36,990
     
29,789
 
                 
NONCURRENT ASSETS
               
Intangible assets, net
   
18,130
     
20,816
 
Property, plant and equipment, net
   
5,475
     
5,756
 
Investment in affiliates
   
-
     
416
 
Other assets
   
415
     
457
 
TOTAL ASSETS
 
$
61,010
   
$
57,234
 
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
CURRENT LIABILITIES
               
Amount due to BioTime, Inc.
 
$
288
   
$
530
 
Accounts payable
   
1,076
     
747
 
Accrued expenses
   
2,495
     
1,183
 
Capital lease liability, current
   
7
     
7
 
Deferred grant income
   
2,185
     
2,513
 
Total current liabilities
   
6,051
     
4,980
 
                 
LONG-TERM LIABILITIES
               
Warrant liability
   
8,665
     
-
 
Capital lease liability, noncurrent
   
20
     
26
 
Deferred tax liabilities, net
   
-
     
2,550
 
Deferred rent liability
   
266
     
179
 
Lease liability
   
3,980
     
4,400
 
TOTAL LIABILITIES
   
18,982
     
12,135
 
                 
Commitments and contingencies (see Note 8)
               
                 
STOCKHOLDERS’ EQUITY
               
Preferred Stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding
   
-
     
-
 
Common Stock, $0.0001 par value, authorized 75,000 Series A Common Stock and 75,000 Series B Common Stock; 47,567 and 38,228 shares Series A Common Stock issued and outstanding at December 31, 2016 and 2015, respectively; no Series B Common Stock issued and outstanding at December 31, 2016 and 2015
   
5
     
4
 
Additional paid-in capital
   
126,829
     
92,900
 
Accumulated other comprehensive income (loss)
   
(1,078
)
   
434
 
Accumulated deficit
   
(83,728
)
   
(48,239
)
Total stockholders’ equity
   
42,028
     
45,099
 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
 
$
61,010
   
$
57,234
 

The accompanying notes are an integral part of these financial statements.
 
45

© Copyright BioTime, Inc.